Case Reports in Endocrinology

Case Reports in Endocrinology / 2014 / Article

Case Report | Open Access

Volume 2014 |Article ID 461816 | 2 pages | https://doi.org/10.1155/2014/461816

Chronic Heroin Dependence Leading to Adrenal Insufficiency

Academic Editor: Anthony J. O’Sullivan
Received20 Jun 2014
Accepted12 Aug 2014
Published20 Aug 2014

Abstract

Opioids have been the mainstay for pain relief and palliation over a long period of time. They are commonly abused by drug addicts and such dependence usually imparts severe physiologic effects on multiple organ systems. The negative impact of opioids on the endocrine system is poorly understood and often underestimated. We describe a patient who developed severe suppression of the hypothalamic-pituitary adrenal (HPA) axis leading to secondary adrenal insufficiency due to long standing abuse of opioids.

1. Introduction

The long term use of opioids for chronic pain or addiction induces widespread endocrine dysfunction which leads to hypogonadism, infertility, fatigue, depression, anxiety, menstrual irregularities, loss of muscle strength, osteoporosis, and compression fractures. The dynamic functioning of the HPA axis can be modulated by a complex series of exogenous and endogenous influence. Opioids bind to specific receptors in the hypothalamus and pituitary gland, disrupt the pulsatile release of corticotrophin releasing hormone (CRH) and adrenocorticotropic hormone (ACTH), and interfere with the production of cortisol and androgen precursors [1]. These patients also have an atypical circadian rhythm due to alteration of the HPA dynamics which contributes further to adrenal insufficiency [2]. Opiates can also mediate a negative impact on the hypothalamic-pituitary gonadal (HPG) axis resulting in hypogonadism [3].

2. Clinical Case

A 35-year-old female patient was referred to the hospital with a random cortisol of 28 nmol/L found on a routine blood test while being investigated for symptoms of tiredness. A detailed history confirmed spells of lethargy, weight loss, and postural dizziness for few months. This was associated with irregular periods, spontaneous galactorrhea with no headaches, or visual symptoms. She has been a heavy user of heroin and mephedrone on a regular basis for four years but discontinued them only 3-4 weeks prior to presenting to her General Practitioner. She was receiving a combination of buprenorphine and naloxone for depression and opioid dependence and was being actively followed up by the mental health team. She also suffered from asthma and used inhalers very infrequently but has never been on steroid preparations on a long term basis.

Her blood pressure was normal with no postural variation. She was clinically euthyroid and euadrenal. Examination of her breasts revealed minimal milky discharge but her visual acuity and field were normal on confrontation perimetry. A thorough systemic examination was entirely normal. Her blood biochemistry suggested normal levels of urea and electrolytes (U/E’s), liver function tests, bone profile, glucose, and plasma osmolality [289 mmol/kg (275–295)], prolactin [182 mU/L (100–500)], LH [4.4 IU/L (2.4–13, follicular phase)], FSH [4.4 IU/L (3.5–13, follicular phase)], and IGF-1 [22.5 nmol/L (9–35)]. Her thyroid function (TFTs) showed a subnormal FT4 [10.2 pmol/L (11–25)] with a normal TSH [2.03 mU/L (0.27–4.2)] and her anti-TPO antibodies were negative [19.4 u/mL (<34)]. A urine toxicology screen confirmed the presence of buprenorphine and benzodiazepines only.

A short synacthen test confirmed adrenal insufficiency with a basal cortisol level of 12 nmol/L and a 30-minute increment to 68 nmol/L (normal > 550 nmol/L) only. Her serum ACTH was low [2.1 pmol/L (4–18)] and the adrenal antibodies were negative. An MRI of pituitary gland was unremarkable. She was commenced on hydrocortisone (20 mg in the morning and 10 mg in the evening) and was followed up in the endocrine clinic. On review, after two months, her symptoms improved remarkably and a repeat biochemistry showed normal U/Es and her TFTs returned to normal (TSH—1.73 mU/L, FT4—11.4 pmol/L) as well.

3. Discussion

Opioid induced endocrinopathy is one of the most common yet least diagnosed and underappreciated consequences of prolonged opioid treatment or abuse. Hypoadrenalism and gonadal steroid depletion have been shown in heroin addicts and in patients on methadone maintenance treatment [3]. The inhibition of the HPA and the HPG axes is mediated by different opioid mechanisms at the hypothalamic level. δ- and κ-opiate receptors appear to be involved in the control of ACTH release, whereas gonadotrophin secretion is modulated by ε-receptors [4]. The impaired pulsatile secretion of CRH due to a variety of putative neurotransmitters and depolarising agents leads to reduced secretion of ACTH and the capacity of the pituitary gland to respond to CRH stimulation [5] which in turn reduces adrenal cortisol production. In addition, there is a dose dependent decrease in adrenal androgen production measured by lowered levels of dehydroepiandrosterone sulphate (DHEAS) [6].

The altered activity of the HPA axis in heroin dependent subjects has been widely studied and is usually characterised by suppressed stress hormone secretion [7]. Injection of diacetylmorphine (DAM) in heroin dependent patients has shown to cause deficit in availability of physiologically active cortisol [8]. Similarly, heroin users also show a decreased HPA activation with metyrapone, a cortisol synthesis inhibitor [9]. Methadone users demonstrate an attenuated response to CRH stimulation and also show a blunted cortisol response to synacthen stimulation [10]. Several individual case reports have also implicated that chronic use of tramadol, fentanyl, and hydromorphone can also lead to adrenocortical insufficiency. Patients with dependence usually have chronically low levels of ACTH and cortisol concentrations which impair an individual’s ability to respond to physical, emotional, and metabolic stressors leading to increased cardiovascular risk, abnormal mental health, bone related complications, and metabolic alterations.

4. Conclusion

Clinicians should be aware of such crucial side effects of prolonged opioid use on the endocrine system as the relationship is complex and can catastrophically alter the metabolic homeostasis. A greater emphasis on the use of nonopioid formulations, opioid rotations, and calibrated opioid maintenance therapy should be undertaken in the management of patients with opioid induced endocrine dysfunction.

Conflict of Interests

The author declares no conflict of interests regarding the publication of this paper.

Supplementary Materials

Supplementary Material: Cortisol, FT3 and FT4 were assayed by electrochemilumincence competitive immunoassay method on Roche MODULAR E170 platform. Hormones like prolactin, FSH, LH, TSH and ACTH were assayed by electrochemilumincence sandwich immunoassay method on Roche MODULAR E170 platform as well. IGF-1 was assayed by Chemilumincence sandwich immunoassay technique on Immuno Diagnosic Systems iSys platform whereas serum osmolality was estimated by freezing point depression method on advanced Instruments osmometer platform.

  1. Supplementary Material

References

  1. C. J. Auernhammer, U. Renner, O.-A. Muller, J. Stalla, and G. K. Stalla, “Loperamide inhibits corticotrophic cell function by a naloxone-insensitive mechanism in the rat in vitro,” Neuroendocrinology, vol. 57, no. 6, pp. 1019–1027, 1993. View at: Publisher Site | Google Scholar
  2. F. Facchinetti, A. Grasso, F. Petraglia, D. Parrini, A. Volpe, and A. R. Genazzani, “Impaired circadian rhythmicity of β-lipotrophin, β-endorphin and ACTH in heroin addicts,” Acta Endocrinologica, vol. 105, no. 2, pp. 149–155, 1984. View at: Google Scholar
  3. A. Pfeiffer and A. Herz, “Endocrine actions of opioids,” Hormone and Metabolic Research, vol. 16, no. 8, pp. 386–397, 1984. View at: Publisher Site | Google Scholar
  4. A. Grossman, P. J. A. Moult, D. Dunnah, and M. Besser, “Different opioid mechanisms are involved in the modulation of ACTH and gonadotrophin release in man,” Neuroendocrinology, vol. 42, no. 4, pp. 357–360, 1986. View at: Publisher Site | Google Scholar
  5. S. Tsagarakis, P. Navara, L. H. Rees, M. Besser, and A. Grossman, “Morphine directly modulates the release of stimulated corticotrophin-releasing factor-41 from rat hypothalamus in vitro,” Endocrinology, vol. 124, no. 5, pp. 2330–2335, 1989. View at: Publisher Site | Google Scholar
  6. H. W. Daniell, “DHEAS deficiency during consumption of sustained action prescribed opioids: evidence for opioid induced inhibition of adrenal androgen production,” Journal of Pain, vol. 7, no. 12, pp. 901–907, 2006. View at: Publisher Site | Google Scholar
  7. M. Walter, H. Gerber, H. C. Kuhl et al., “Acute effects of intravenous heroin on the hypothalamic-pituitary-adrenal axis response: a controlled trial,” Journal of Clinical Psychopharmacology, vol. 33, no. 2, pp. 193–198, 2013. View at: Publisher Site | Google Scholar
  8. H. Gerber, S. J. Borgwardt, O. Schmid et al., “The impact of diacetylmorphine on hypothalamic-pituitary-adrenal axis activity and heroin craving in heroin dependence,” European Addiction Research, vol. 18, no. 3, pp. 116–123, 2012. View at: Publisher Site | Google Scholar
  9. P. Cushman Jr., “Some endocrine and immunological observation in heroin and methadone maintained opioid addicts,” in The Social and Medical Aspects of Drug Abuse, G. Serban, Ed., Spectrum Publications, 1984. View at: Google Scholar
  10. C. A. Dackis, M. Gurpegui, A. L. C. Pottash, and M. S. Gold, “Methadone induced hypoadrenalism,” The Lancet, vol. 2, no. 8308, p. 1167, 1982. View at: Google Scholar

Copyright © 2014 Gautam Das. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

5224 Views | 559 Downloads | 2 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.